



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/753,008	01/02/2001	Stefan Somlo	96700/658	1280
7590	04/14/2004		EXAMINER	
AMSTER, ROTHSTEIN & EBENSTEIN Attorneys for Applicants 90 Park Avenue New York, NY 10016			LU, FRANK WEI MIN	
			ART UNIT	PAPER NUMBER
			1634	

DATE MAILED: 04/14/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

8M

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/753,008	SOMLO ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Frank W Lu	1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

#### A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 24 March 2003.
- 2a) This action is **FINAL**.                    2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 76-81 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) 76-81 is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on 02 January 2001 is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) All
  - b) Some \*
  - c) None of:
    1. Certified copies of the priority documents have been received.
    2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 3/24/2003.
- 4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_.

**DETAILED ACTION**

***Election/Restrictions***

1. In applicant's response to previous restriction, applicant indicates that claims 1-75 has been canceled in the amendment filed on October 24, 2001. After reviewing the restriction made by previous examiner in other art unit and applicant's response filed on March 24, 2003, the examiner agrees to withdraw the restriction made on March 11, 2003. Therefore, claims 76-81 will be examined.

***Specification***

2. The disclosure is objected to because of the following informalities. (1) applicant indicates that this instant application is a continuation of cases 09/385,752 and 08/651,999 in the first sentence of the specification. However, it is unclear that applicant claims priority for the cases 09/385,752 and 08/651,999 or not; (2) there are Figure 5A to 5G. However, the Brief Description of the Figures only describes Figure 5; and (3) in page 12 of the specification, there are several nucleotide sequences that have more than 10 nucleotides. However, these nucleotide sequences are without SEQ ID Nos.

Appropriate correction is required.

***Claim Objections***

3. Claims 76 and 79 are objected to because of the following informality: "the PKD2 gene" should be "PKD2 gene".

4. Claim 79 is objected to because of the following informality: "wherein the mutation comprises one or more deletion, insertion, point, or rearrangement mutations" should be "wherein the mutation comprise deletion, insertion, point, or rearrangement mutation". Appropriate correction is required.

***Claim Rejections - 35 USC § 112***

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 76-81 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for performing the methods recited in claims 76-81 by comparing PKD2 gene in a polynucleotide sample with its wild-type PKD2 gene, does not reasonably provide enablement for the methods recited in claims 76-81 by comparing PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

In *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) the court considered the issue of enablement in molecular biology. The Court summarized eight factors to be considered in a determination of "undue experimentation". These factors include: (a) the quantity of experimentation necessary; (b) the amount of direction or guidance presented; (c) the presence or absence of working examples; (d) the nature of the invention; (e) the state of the prior art; (f) the relative skill of those in the art; (g) the predictability of the art; and (h) the

breadth of the claims. The Court also stated that although the level of skill in molecular biology is high, results of experiments in molecular biology are unpredictable.

To begin, there is no direction or guidance to perform the methods recited in claims 76-81 by comparing PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species. While the relative skill in the art is very high (the Ph.D. degree with laboratory experience), there is no predictability whether the methods recited in claims 76-81 can be performed by comparing PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species.

Claims 76-81 are directly to a method of detecting the presence or absence of a mutation in the sequence of PKD2. The specification only describes a method of detecting the presence or absence of a mutation in the sequence of PKD2 by comparing human PKD2 gene in a polynucleotide sample with human wild-type gene. However, the specification does not provide guidance for a method of detecting the presence or absence of a mutation in the sequence of PKD2 by comparing PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species. Because the specification does not provide an evidence to show that SEQ ID NO: 6 (human PKD2 with GeneBank Accession No: U50928) is identical among all species, it is unclear whether a method of detecting the presence or absence of a mutation in the sequence of PKD2 can be performed by comparing PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species. In fact, sequence searching shows that SEQ ID NO: 6 (human PKD2) is only partially homologous to murine PKD2 but is not identical to murine PKD2 (see attached results from sequence searching). This suggests that it is impossible to perform the methods recited in claims 76-81 by comparing

PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species.

With these unpredictable factors, the skilled artisan will have no way to predict the experimental results. Accordingly, it is concluded that undue experimentation is required to make the invention as it is claimed. These undue experimentations at least includes to test whether that the methods recited in claims 76-81 can be performed by comparing PKD2 gene from one species in a polynucleotide sample with a wild-type PKD2 gene from other species.

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 76-81 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

9. Claim 76 is rejected as vague and indefinite. Since the step (a) of the claim does not indicate that a polynucleotide sample has PKD2 gene, it is unclear how the difference between the polynucleotide sample and the reference wild-type PKD2 sequence are mutations of PKD 2 gene. Furthermore, the claim does not indicate what gene has “mutations which comprise one or more deletion, insertion, point, or rearrangement mutations”. Please clarify.

10. Claim 76 is rejected as vague and indefinite. Although the claim is directed to a method of detecting the presence or absence of a mutation in the sequence of PKD2 gene, there is no method step in the claim for Claim 76 is rejected as vague and indefinite and the goal (preamble) can not reach. Please clarify.

Art Unit: 1634

11. Claim 79 is rejected as vague and indefinite. Since the step (a) of the claim does not indicate that a polynucleotide sample has PKD2 gene, it is unclear how performing sequence analysis of the polynucleotide sample can detect the presence or absence of a mutation in the sequence of the PKD2 gene of the subject. Please clarify.

12. Claim 79 recites the limitation "the sequence of the PKD2 gene of the subject" in the claim. There is insufficient antecedent basis for this limitation in the claim because step (a) does not indicate that a subject has a PDK2 gene. Please clarify.

### ***Double Patenting***

13. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

14. Claims 76-81 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-3 of U.S. Patent No. 6,228,591 B1. Although the conflicting claims are not identical, they are not patentably distinct from each other because the examined claims in this instant application is either anticipated by, or would have been obvious over, the reference claims. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*,

Art Unit: 1634

686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). Although claims 76 and 79 in this instant application are not identical to claim 1 of US Patent No. 6,228,591 B1, claim 1 in US Patent 6,228,591 B1 is directed to the same subject matter and fall entirely within the scope of claims 76 and 79 in this instant application. In other words, claims 76 and 79 in this instant application are anticipated by claim 1 of US Patent No. 6,228,591 B1. Note that claims 77, 78, 80, and 81 are identical to claims 2 and 3 of US Patent No. 6,228,591 B1.

### ***Conclusion***

15. No claim is allowed.
16. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 872-9306 or (703)305-3014.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (571)272-0782.

Art Unit: 1634

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.



Frank Lu  
PSA  
April 9, 2004

FRANK LU  
PATENT EXAMINER



results of BLAST

**BLASTN 2.2.8 [Jan-05-2004]****Reference:**

Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schäffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402.

RID: 1081784038-16067-188708913800.BLASTQ3


**Query=**

(5073 letters)

**Database:** All GenBank+EMBL+DDBJ+PDB sequences (but no EST, STS, GSS, or phase 0, 1 or 2 HTGS sequences)

2,226,501 sequences; 10,398,606,914 total letters

If you have any problems or questions with the results of this search please refer to the [BLAST FAQs](#)

[Taxonomy reports](#)**Distribution of 3819 Blast Hits on the Query Sequence**

Sequences producing significant alignments:

Score (bits)	E Value
--------------	---------

gi 33286447 ref NM_000297.2	Homo sapiens polycystic kidney...	5453	0.0	
gi 1373168 gb U50928.1 HSU50928	Human autosomal dominant po...	5453	0.0	
gi 1477691 gb U56813.1 HSU56813	Human polycystin mRNA, par...	3895	0.0	

<a href="#">gi 38565985 gb BC062969.1 </a>	Mus musculus polycystic kidney d...	<u>2319</u>	0.0	
<a href="#">gi 31419361 gb BC053058.1 </a>	Mus musculus polycystic kidney d...	<u>2319</u>	0.0	
<a href="#">gi 4150864 emb Y13278.1 MMPOLCYST</a>	Mus musculus mRNA for pol...	<u>2311</u>	0.0	
<a href="#">gi 26343500 dbj AK053502.1 </a>	Mus musculus 0 day neonate eyeb...	<u>2311</u>	0.0	
<a href="#">gi 2558834 gb AF014010.1 AF014010</a>	Mus musculus polycystic k...	<u>2309</u>	0.0	
<a href="#">gi 31543486 ref NM_008861.2 </a>	Mus musculus polycystic kidney...	<u>2309</u>	0.0	
<a href="#">gi 34536625 dbj AK128961.1 </a>	Mus musculus cDNA fis, clone TR...	<u>2165</u>	0.0	
<a href="#">gi 11128446 gb AC084732.1 AC084732</a>	Homo sapiens BAC clone R...	<u>1742</u>	0.0	
<a href="#">gi 6855623 gb AF113693.1 AF113693</a>	Homo sapiens clone FLB5135	<u>1739</u>	0.0	
<a href="#">gi 3005705 gb AF054992.1 AF054992</a>	Homo sapiens clone 23778 ...	<u>1723</u>	0.0	
<a href="#">gi 3126903 gb AF004873.1 HSPKD15</a>	Homo sapiens autosomal dom...	<u>1655</u>	0.0	
<a href="#">gi 4107256 emb Y14120.1 MMY14120</a>	Mus musculus mRNA for poly...	<u>860</u>	0.0	
<a href="#">gi 3126889 gb AF004859.1 HSPKD01</a>	Homo sapiens autosomal dom...	<u>694</u>	0.0	
<a href="#">gi 3126892 gb AF004862.1 HSPKD04</a>	Homo sapiens autosomal dom...	<u>502</u>	e-138	
<a href="#">gi 15871680 emb AJ327262.1 HSA327262</a>	Homo sapiens genomic s...	<u>464</u>	e-127	
<a href="#">gi 3126894 gb AF004864.1 HSPKD06</a>	Homo sapiens autosomal dom...	<u>460</u>	e-125	
<a href="#">gi 3126893 gb AF004863.1 HSPKD05</a>	Homo sapiens autosomal dom...	<u>450</u>	e-122	
<a href="#">gi 15875582 emb AJ331164.1 HSA331164</a>	Homo sapiens genomic s...	<u>381</u>	e-101	
<a href="#">gi 3126896 gb AF004866.1 HSPKD08</a>	Homo sapiens autosomal dom...	<u>365</u>	6e-97	
<a href="#">gi 3126895 gb AF004865.1 HSPKD07</a>	Homo sapiens autosomal dom...	<u>335</u>	5e-88	
<a href="#">gi 3126901 gb AF004871.1 HSPKD13</a>	Homo sapiens autosomal dom...	<u>327</u>	1e-85	
<a href="#">gi 4150862 emb Y14105.1 MMY14105</a>	Mus musculus pkd2 exon 1 a...	<u>321</u>	8e-84	
<a href="#">gi 3126902 gb AF004872.1 HSPKD14</a>	Homo sapiens autosomal dom...	<u>295</u>	5e-76	
<a href="#">gi 4107461 emb Y14110.1 MMY14110</a>	Mus musculus pkd2 exon 6	<u>278</u>	1e-70	
<a href="#">gi 3126891 gb AF004861.1 HSPKD03</a>	Homo sapiens autosomal dom...	<u>266</u>	4e-67	
<a href="#">gi 7531965 gb AF004867.2 HSPKD09</a>	Homo sapiens autosomal dom...	<u>240</u>	2e-59	
<a href="#">gi 3126900 gb AF004870.1 HSPKD12</a>	Homo sapiens autosomal dom...	<u>238</u>	9e-59	
<a href="#">gi 3126890 gb AF004860.1 HSPKD02</a>	Homo sapiens autosomal dom...	<u>230</u>	2e-56	
<a href="#">gi 4107459 emb Y14108.1 MMY14108</a>	Mus musculus pkd2 exon 4	<u>226</u>	3e-55	
<a href="#">gi 3126899 gb AF004869.1 HSPKD11</a>	Homo sapiens autosomal dom...	<u>200</u>	2e-47	
<a href="#">gi 3126898 gb AF004868.1 HSPKD10</a>	Homo sapiens autosomal dom...	<u>200</u>	2e-47	
<a href="#">gi 4107463 emb Y14112.1 MMY14112</a>	Mus musculus pkd2 exon 8	<u>198</u>	8e-47	
<a href="#">gi 10121558 gb AF242389.1 AF242389</a>	Mus musculus autosomal d...	<u>196</u>	3e-46	
<a href="#">gi 4107458 emb Y14107.1 MMY14107</a>	Mus musculus pkd2 exon 3	<u>170</u>	2e-38	
<a href="#">gi 15872509 emb AJ328091.1 HSA328091</a>	Homo sapiens genomic s...	<u>168</u>	7e-38	
<a href="#">gi 4107468 emb Y14113.1 MMY14113</a>	Mus musculus pkd2 exon 9	<u>161</u>	2e-35	
<a href="#">gi 15871676 emb AJ327258.1 HSA327258</a>	Homo sapiens genomic s...	<u>157</u>	3e-34	
<a href="#">gi 4107472 emb Y14117.1 MMY14117</a>	Mus musculus pkd2 exon 13	<u>153</u>	4e-33	
<a href="#">gi 4150881 emb Y14111.1 MMY14111</a>	Mus musculus pkd2 exon 7	<u>149</u>	7e-32	
<a href="#">gi 27802045 gb AC011084.17 </a>	Homo sapiens chromosome 11, clo...	<u>139</u>	6e-29	
<a href="#">gi 4107471 emb Y14116.1 MMY14116</a>	Mus musculus pkd2 exon 12	<u>135</u>	1e-27	
<a href="#">gi 18139513 gb AC069281.6 </a>	Homo sapiens BAC clone RP11-44M6...	<u>133</u>	4e-27	
<a href="#">gi 5002592 emb Y17457.1 HOSA17457</a>	Homo sapiens LSFR3A gene,...	<u>131</u>	2e-26	
<a href="#">gi 18650683 emb AL445931.29 </a>	Human DNA sequence from clone ...	<u>131</u>	2e-26	
<a href="#">gi 34530661 dbj AK124783.1 </a>	Homo sapiens cDNA FLJ42793 fis,...	<u>131</u>	2e-26	
<a href="#">gi 12717949 emb AL158207.15 </a>	Human DNA sequence from clone ...	<u>131</u>	2e-26	
<a href="#">gi 2251212 gb AC002293.1 AC002293</a>	Genomic sequence from Hum...	<u>131</u>	2e-26	
<a href="#">gi 2583102 gb AC002102.1 AC002102</a>	Homo sapiens chromosome 9...	<u>131</u>	2e-26	
<a href="#">gi 26096354 dbj AK054397.1 </a>	Mus musculus 2 days pregnant ad...	<u>131</u>	2e-26	
<a href="#">gi 4107457 emb Y14106.1 MMY14106</a>	Mus musculus pkd2 exon 2	<u>127</u>	2e-25	
<a href="#">gi 19033426 gb AC018450.26 </a>	Homo sapiens 3 BAC RP11-80H8 (R...	<u>127</u>	2e-25	

gi 9408726 emb AL023803.3 HS616B8	Human DNA sequence from c...	125	9e-25	L G
gi 30522921 gb AC096537.3	Homo sapiens chromosome 1 clone ...	123	4e-24	
gi 23396277 gb AC124914.3	Homo sapiens chromosome 3 clone ...	123	4e-24	
gi 1669681 emb Z82901.1 HS506G2A	Human DNA sequence from cl...	123	4e-24	
gi 15142005 emb AL513185.12	Human DNA sequence from clone ...	123	4e-24	
gi 15962561 emb AL357037.13	Human DNA sequence from clone ...	123	4e-24	
gi 29293996 gb AC080129.26	Homo sapiens 3 BAC RP11-135A1 (...)	123	4e-24	
gi 28973812 gb AC116351.2	Homo sapiens chromosome 5 clone ...	123	4e-24	
gi 21427846 gb AC040977.10	Homo sapiens chromosome 17, clo...	123	4e-24	
gi 27877146 gb AC124890.8	Homo sapiens 12 BAC RP11-450G15 ...	123	4e-24	
gi 16328249 gb AC008614.6	Homo sapiens chromosome 5 clone ...	123	4e-24	
gi 27764204 emb AL109767.7 CNS018OX	Human chromosome 14 DNA...	123	4e-24	
gi 4107460 emb Y14109.1 MMY14109	Mus musculus pkd2 exon 5	123	4e-24	L
gi 2329922 gb AC002404.1 AC002404	Human Chromosome X PAC RP...	123	4e-24	
gi 16555592 emb AL132819.6 CNS01DTO	Human chromosome 14 DNA...	123	4e-24	
gi 41324131 gb AY527817.1	Homo sapiens arachidonate 12-lip...	123	4e-24	
gi 18476640 emb AL512643.9	Human DNA sequence from clone R...	123	4e-24	
gi 22324235 emb AL121602.34 HSDJ636H5	Human DNA sequence fr...	123	4e-24	
gi 21617782 gb AC097662.5	Homo sapiens BAC clone RP11-563C...	121	1e-23	
gi 21735134 gb AC079097.6	Homo sapiens chromosome 8, clone...	121	1e-23	
gi 18997243 gb AC008665.6	Homo sapiens chromosome 5 clone ...	121	1e-23	
gi 18482321 gb AC079776.5	Homo sapiens BAC clone RP11-315H...	121	1e-23	L
gi 11225364 gb AC044787.6 AC044787	Homo sapiens chromosome ...	121	1e-23	
gi 16943977 emb AL353093.18	Human DNA sequence from clone ...	121	1e-23	
gi 2982169 gb AC004381.1 HUAC004381	Homo sapiens Chromosome...	119	6e-23	L G
gi 6630488 gb AC008149.14	Homo sapiens 12 BAC RP11-394J1 (...)	119	6e-23	L G
gi 2578066 emb Z98036.1 HS187N21	Human DNA sequence from cl...	119	6e-23	
gi 20334687 gb AC084871.4	Homo sapiens BAC clone RP11-701P...	119	6e-23	
gi 28626577 gb AC008121.43	Homo sapiens 12 BAC RP11-407N8 ...	119	6e-23	
gi 21070548 gb AC013242.8	Homo sapiens chromosome 10 clone...	119	6e-23	
gi 20330874 gb AC099784.2	Homo sapiens chromosome 1 clone ...	119	6e-23	
gi 25815264 gb AC131011.5	Homo sapiens X BAC RP13-314C10 (...)	119	6e-23	L
gi 19697510 gb AC107051.4	Homo sapiens BAC clone RP11-224D...	119	6e-23	
gi 19551200 gb AC084353.5	Homo sapiens BAC clone RP11-592K...	119	6e-23	
gi 15321576 gb AC079922.5	Homo sapiens BAC clone RP11-368A...	119	6e-23	
gi 32490467 dbj AP006545.1	Homo sapiens genomic DNA, chrom...	119	6e-23	
gi 31745092 dbj AP001028.7	Homo sapiens genomic DNA, chrom...	119	6e-23	
gi 22202654 dbj AP001029.5	Homo sapiens genomic DNA, chrom...	119	6e-23	
gi 2547406 gb AF024533.1 AF024533	Homo sapiens cosmid 123E1...	119	6e-23	
gi 3694626 gb AC005764.1 AC005764	Homo sapiens chromosome 1...	119	6e-23	G
gi 25136942 emb AL591845.27	Human DNA sequence from clone ...	119	6e-23	
gi 4107474 emb Y14119.1 MMY14119	Mus musculus pkd2 exon 15	119	6e-23	L
gi 3056603 gb AC004560.1 AC004560	Homo sapiens chromosome 1...	119	6e-23	
gi 19034023 gb AC005088.3	Homo sapiens BAC clone CTA-313A1...	119	6e-23	G
gi 41350103 gb AC146278.3	Pan troglodytes chromosome X clo...	119	6e-23	
gi 8218068 emb AL078590.28 HSA557H15	Human DNA sequence fro...	119	6e-23	

**Alignments**

>gi|33286447|ref|NM\_000297.2| L Homo sapiens polycystic kidney disease 2 (auto mRNA







Sbjct: 2349 atgccatctcagagagtctccggcaagggtggcaaactgaacttgcgatgacttcggc 2408

Query: 2294 aagatctcaaaggaaaggggccatactgatgcagagattgaggcaatattcacaagtacg 2353  
|||| || || || || || || || || || || || || || || || || || || || || || |

Sbjct: 2409 aagacctgaaaggaaaggggccatacagatgcagagattgaggccatattcactaatatg 2468

Query: 2354 accaagatggagaccaagaactgaccgaacatgaacatcagcatgagagacgacttgg 2413  
|||| || || || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2469 accaggatggcgaccaggaaactgaccgagcgtgagcatcaacagatgagagatgacttgg 2528

Query: 2414 agaaaagagagggaggacacctggattggatcacagtttaccacgtcccattgagcagcc 2473  
|||| || || || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2529 agaaagagagggaggacaccttagacttggAACACAGCTTTACCACGTCCATTGAGCAGCA 2588

Query: 2474 gaagttccctcgaaaggctggatgactctgaggaggatgacgatgaagatagcggacata 2533  
|||| || || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2589 gaagttccccagaaggctggatgactccgaggaggatgacgaagacagtggccata 2648

Query: 2534 gctccagaaggaggaaaggcattcttagtggcgtttacgaagagttcaagtcctgg 2593  
|||| || || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2649 gctccaggaggaggaaaggcatctccagtggggtttctatgaagagttccaagttactgg 2708

Query: 2594 tgagacgagtggaccggatggagcattccatcgccagcatagtgccaagattgacgccc 2653  
|||| || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2709 tgaggcgcgtggaccgcatggagcactccattggcagcatcgttccaagattgatgccc 2768

Query: 2654 tgatcgtaagcttagagattatggagcggccaaactgaagagggggaggtgctggaa 2713  
|||| || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2769 tgattgtcaagctggagatcatggagcggccaaactgaagagacgagaggtttaggac 2828

Query: 2714 ggctgtggatgggtggccgaggatgaaaggctgggtcgacagtgaatccatagg 2773  
|||| || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2829 ggctgtggatggcgtggctgaggatgcgcactgggtcgggacagtggatccacagg 2888

Query: 2774 aacagatggaaacggctagtagtgcgtgaagagttggAACGCTGGATCCGATGTCAGCTT 2833  
| || || || || || || || || || || || || || || || || || || || || ||

Sbjct: 2889 agcagatggagcgcctggcggaaagagctggagcgcgtggatccgatgtcagctt 2948

Query: 2834 cccagatcgtcatgttttaggcacgccagtggactaaatggtaacacctcgccccagaa 2893  
| || | || || || || || || | || || || || || || || || || || || ||

Sbjct: 2949 cgcaaacaggcatggtaagcacacaactggactcggtggccagccccccccagaa 3008

Query: 2894 gctccggccatctcctccaaatctacagaaggcatggaaagggtgcagggtggaaatgg 2951  
| | || || || || || || || || || || || || || || || || || || || ||

Sbjct: 3009 acccgccctcttcctccactgtcgagaggcctggaaagggtggaggtggaaatgg 3066

Score = 196 bits (99), Expect = 3e-46

Identities = 159/179 (88%)  
Strand = Plus / Plus

Query: 175 ggcgccagccctgcccggggggccctgtcgagcagcggggcctggagatcgatgt 234  
||| ||| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |  
Sbjct: 284 ggcgccggccctagctgtccccggggccctggggagcagcggggcctggagatcgatgt 343

Query: 235 cagcgcatccggcaggcgccgcgcgggacccccccggccggagccgcggcctcccttc 294  
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Sbjct: 344 gagcgcatccggcaggcgccgcgtcggtatccccccggccggagccgcggcctcgccgtct 403

Query: 295 cctccgcgtctcggtggccggcggccggataccggcttcggagc 353  
||||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Sbjct: 404 cctccgcttcgtcctgtccaggcaagcgtggagccgcgacaaccggcttgaggc 462

Score = 71.9 bits (36), Expect = 1e-08  
Identities = 40/68 (58%)  
Strand = Plus / Plus

Query: 43 nnnnnnnnnnnnnnnnnnnnnnnnnnatggtaactccaggctcgctgcagcctcagcagccc 102  
                  ||||| ||||||||| ||||||||| ||||| |||||  
Sbjct: 164 gcgcgctggcgccaggatggtaactccagacgcgtgcagccgcagccccc 223

Query: 103 ggggacgc 110  
          |||||||  
Sbjct: 224 ggggacgc 231

Score = 56.0 bits (28), Expect = 7e-04  
Identities = 55/63 (87%), Gaps = 2/63 (3%)  
Strand = Plus / Plus

Query: 3071 gatgcttagtcttgtgaccgatttgta--atcttctgcacttaatttattttatataaa 3128  
          ||||||| ||||||||| ||||| ||  ||  ||||||| ||||||||| |||||  
Sbjct: 3185 gatgctggctttgtgaccaatttgtataatttctgcacttaatttacgtaaa 3244

Query: 3129 ctt 3131  
          |||  
Sbjct: 3245 ctt 3247

Score = 50.1 bits (25), Expect = 0.045  
Identities = 25/25 (100%)  
Strand = Plus / Plus

```
Query: 3172 agaaatctaggtgtaaatattgagt 3196
          ||||||| | | | | | | | | | | | | | |
Sbjct: 3291 agaaatctaggtgtaaatattgagt 3315
```



Web site: <http://www-shgc.stanford.edu>  
Contact: (Dickson, Mark) mcd@paxil.stanford.edu  
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers, R. M.

Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: IRAK Plate: 114 Row: p Column: 18  
This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 6679356.

FEATURES	Location/Qualifiers
<u>source</u>	1..3919 /organism="Mus musculus" /mol_type="mRNA" /strain="C57BL/6" /db_xref="taxon:10090" /clone="MGC:62348 IMAGE:6409512" /tissue_type="Brain, enriched mouse brain 12.5dp" /clone_lib="NIH_BMAP_FOO" /lab_host="DH10B" /note="Vector: pYX-ASC"
<u>gene</u>	1..3919 /gene="Pkd2" /db_xref="LocusID: <a href="#">18764</a> " /db_xref="MGI: <a href="#">1099818</a> "
<u>CDS</u>	188..3088 /gene="Pkd2" /codon_start=1 /product="Pkd2 protein" /protein_id="AAH53058.1" /db_xref="GI:31419362" /db_xref="LocusID: <a href="#">18764</a> " /db_xref="MGI: <a href="#">1099818</a> " /translation="MVNSRRVQPQPPGDAGRSPAPRASGPGRLVAGGAGLAVPGGLGE QRGLEIEMERIRQAAARDPPAGASASPSPPLSSCSRQAWSRDNPGFEAEEDDDDEVE GEEGGMVVEDMVEWRPGSRRSASSSAVSSVGARGRLGLSYRGAHLSGRRRLEDQGA QCPSPAGGGDPLRHLPLEGQPPRVAWAERLVRGLRGLWGTRLMEESNANREKYLKSV LRELVTYLFVLVLCILTYGMSSNVYYTRTLSQLFIDTPVSKTEKTNFKTLSSMED FWKFTEGSFLDGLYWKAQTSNHTQADNRSFIFYENLLLGVPRLRQLRVNGSCSIQD LRDEIKECYDVYSVSSEDRAPFGPRNGTAWMYTSEKELNGSHWGIIASYSGAGYYLD LSRTREETAAQLAGLRRNFWLDRGTRAFAFIDFSVYNANINLFCVVRLIAEFFPATGGVV PSWQFQPVKLIRYVTAFDFFLAACIEIFCFIYYVVEEILEIRIHLRSYFRSFVNCL DVIVIVLSVSVAMVINIYRMSNAEGLLQFLEDQNSFPNFEHVAYWQIQFNNISAVMFL VWIKLFKFINFNRNTMSQLSTTMSRAKDLFGFTIMFSIIFLAYAQLAYLVFGTQVDDF STFQECIFTQFRIILGDINFAIEEANRVLGPLYFTTFVFFMFILLNMFLAIINDSY SEVKSDLAQQAEMELSDLIRKGCKQKALVKLKLKRNTVDAISESLRQGGGKLNFDLRL QDLKGKGHTDAEIEAIFTKYDQDGDQELTEREHQMRDDLEKEREDLDLEHSSLPRPM SSRSFPRSLDDSEEDDEDSGHSSRRGSISSGVSYEEFQVLVRRVDRMEHSIGSIVS KIDAVIVKLEIMERAKLKREVLRGRLLDGVAEDARLGRDSEIHREQMERLVREELRW ESDDAASQTGHGVSTQVGLGGQPHPRNPRPPSSQSAEGLEGGGGNGSANVHA" 1847..2110 /gene="Pkd2" /note="ion_trans; Region: Ion transport protein. This family contains Sodium, Potassium, Calcium ion channels. This family is 6 transmembrane helices in which the last two helices flank a loop which determines ion selectivity. In some sub-families (e.g. Na channels) the domain is repeated four times, whereas in others (e.g. K channels) the protein forms as a tetramer in the membrane. A bacterial structure of the protein is known for the last

two helices but is not the Pfam family due to it lacking  
the first four helices"  
/db\_xref="CDD:pfam00520"

variation 2998  
/gene="Pkd2"  
/allele="G"  
/allele="C"  
/db\_xref="dbSNP:3661613"

variation 3011  
/gene="Pkd2"  
/allele="T"  
/allele="C"  
/db\_xref="dbSNP:3661637"

variation 3073  
/gene="Pkd2"  
/allele="T"  
/allele="C"  
/db\_xref="dbSNP:3662096"

variation 3240  
/gene="Pkd2"  
/allele="G"  
/allele="A"  
/db\_xref="dbSNP:3663200"

variation 3301  
/gene="Pkd2"  
/allele="G"  
/allele="A"  
/db\_xref="dbSNP:3663308"

variation 3342  
/gene="Pkd2"  
/allele="T"  
/allele="C"  
/db\_xref="dbSNP:3663824"

variation 3348  
/gene="Pkd2"  
/allele="T"  
/allele="G"  
/db\_xref="dbSNP:3663832"

variation 3451  
/gene="Pkd2"  
/allele="T"  
/allele="C"  
/db\_xref="dbSNP:3664429"

## ORIGIN

1 ggatccctgg ccgctggggc ctttcgacg cgccctaagtc cagtccaggg gaggccaggg  
61 cccgggaggg gggccgaggg ggcggggcgg agcaggccga ctccgggaag  
121 aaaagaacat ggctcctgcg gcagagggcg gcccactcc cgggcgcgct gggccgccagt  
181 gagcgcctatgtttaactcca gacgcgtgca gccgcagccg cccggggacg cgggacgctc  
241 gccccgcggc cgagcgtccg gaccggggcg cctgggtggcg ggaggcgccg gcctagctgt  
301 ccccgccgc ctcggggagc agcggggcct ggagatcgat atggagcgca tccggcaggc  
361 ggccgcctcg gatcccccg ccggagcctc ggcctcgccg tctcctccgc tttcgctctg  
421 ctccaggcaa gcgtggagcc ggcacaaccc gggcttgag gcagaggagg atgacgacga  
481 cgacgaggta gaaggagaag aaggaggat ggtggtagag atggatgtgg atgtggcgccc  
541 gggcagtcgg aggtcggcct ctcctcgcc cgtgagctcg gtggcgccg gcccggagg  
601 gtcggggagc taccgcggcg cggctcacct gagcggggagg cggcgcggc tagaggacca  
661 gggcgcgcag tgtcccgcc ccgcggggcgg cggggacccg ctgcatacgcc acctcccgct  
721 ggaggggccag ccaccccgag tggcctgggc agagaggctg gtgcgaggc tgcgaggct  
781 ctggggaaaca agactcatgg aagagagcaa cgccaaaccga gagaagtacc tgaaaagtgt  
841 gttaaaaaatggatgtt actactacac tcggacactg tcacagctat tcatacgacac  
901 catatgtgttccaaatgtgtt actactacac tcggacactg tcacagctat tcatacgacac

961 cccagtgtcg aaaacagaga aaaccaactt taaaactctt tcttccatgg agaggctcgt  
1021 gaagttcacc gaaggctcct tcctggatgg gctgtactgg aaggcacaga ccagcaacca  
1081 cacgcgaagct gacaaccgaa gctttatctt ctatgagaac ctgtcttag gagtgcccg  
1141 ttcacgcctt ctccgagtca gaaacggatc ctgcctccat cctcaggacc tgcgagatga  
1201 aattaaagag tgctatgacg tctactccgt cagcagttag gacagagtc cattggacc  
1261 gcggaatgga actgcgtgga tgtacacaag tgagaaggag ctgaatggga gcagtcactg  
1321 ggggatcatt gcgtcgtaca gtggagcggg ttactacctg gatctgtcca gaaccaggga  
1381 ggagacagca gcccagctt ctggcctcag gaggaacttc tggctggacc gggcacgc  
1441 ggcagcttt atagacttct cggtgtataa cgcaaacatt aacctgttct gtgtggctag  
1501 gttattggcg gagttcccag caacgggtgg cgtgtaccc tcttggcagt ttcaagctgt  
1561 aaaactgatc cgctatgtca cagccttga tttcttctg gcagcctgt agatcatctt  
1621 ttgtttctt atcatttact atgtgggtgga agagatattt gaaattcgga ttcacagact  
1681 gagctatttcc aggagtttct ggaattgtct ggtgttgg attgtcggt tatctgttagt  
1741 agctatgggtt attaacattt accgaatgtc aaatgcagag gggctgtac agttcttga  
1801 agatcaaaat tctttccccca actttgagca tgtgcatac tggcaaatac agtcaacaa  
1861 tataagtgt gtcatggat tttggctcg gattaagtc ttcaatttca tcaattttaa  
1921 taggaccatg agccagctct ccacaaccat gtctcgatgt gccaaagacc tcttcggctt  
1981 caccataatg ttctccatca tttcttggc atacgcacag ctggcatacc ttgttctcg  
2041 caccgcgtc gatgacttca gcactttcca agaatgttac ttcacccagt tccgcatacat  
2101 ttgggtgtat atcaacttccg cagagatcga ggaagctaactt ctagtttccg  
2161 ttttactaca ttgtgttct ttatgttctt catttttttgc aatatgttcc tggcgatcat  
2221 caatgattcg tactctgaaatg tgaatccgatc tctggcccg  
2281 ctcagacctt atcagaaaagg gtcgcacaaa agcactggc  
2341 cactgttagat gccatctcg agagtctcg gcaagggtgt  
2401 gcttcggcaa gacctgaaag ggaagggcatac  
2461 taaatatgac caggatggcg accaggaact gaccgagcgt  
2521 tgacttggag aaagagaggg aggacctaga cttgaaacac  
2581 gaggcagcaga agtttccccca gaaggctcgatc tgactcccg  
2641 tggccatagc tccaggagga gggggaaatcgatc ctccagtg  
2701 agtactgggtt aggcgcgtgg accgcatacgatc  
2761 tgatggcgatc attgtcaagc tggagatcat ggcggggcc  
2821 gtttaggacgg ctgctggatc gcgtggctga ggatgcgcga  
2881 ccacaggaggatc cagatggagc gcctggcg  
2941 tgcagcttc caaacaggatc atgggtgtaa cacacaactt  
3001 cccccagaaac ccgcgccttc cttccctccatc  
3061 aaatggaaatg gccaacgtcc atgcctaata atccacacat  
3121 ccgagaggatc gctgtccatc acgacaatgt  
3181 ttatgtatgtt ggtctttgtt accaatttgtt ataattttct  
3241 taaaacttaaa cccgtggatc aaggaaggatc tgcattactt  
3301 gtgtaaatat tgagttcaga aagaagaaaa ctttggaaatgt  
3361 ccgtgtcttc aggtgacatc gtttggaaatgt  
3421 gtggagccac cacagtctgc tgcattactc  
3481 tttcattcca ctgaggatata actcgagatc tactgcataat  
3541 agtatttcag caacccttctt ggggtgcaga gaaaggatat  
3601 aatgtgtgtt aacagtgttgc atagatgtca  
3661 atcatttaat ttttggatc ttttagctt  
3721 taagttcata tattttctt ctttagtctt  
3781 agtctccctt ctgttaaggatc  
3841 aacaatttctt taactgttaat aatgtgtaca ttacttaata  
3901 aaaaaaaaaaaaaaaa

11